论文部分内容阅读
目的 研究阿胶强骨口服液(donkey-hide glue reinforcing bone oral solution, DGRBOS) 对SD大鼠血液25-羟基维生素D3 (25-OH-VD3)、1,25-羟基维生素D3(1,25-(OH)2-VD3)和肝脏VDR基因表达的影响,探讨DGRBOS治疗骨质疏松的疗效机制.方法 6月龄SD大鼠36只, 随机分为A组(假手术组),B组(卵巢切除+生理盐水组),C组(卵巢切除+阿胶强骨口服液组),每组12只.6个月后取材检测.采用ELISA法对去势大鼠血清25-OH-VD3和1,25-(OH)2-VD3进行研究,用荧光定量PCR对肝脏VDR基因进行定量分析.结果 C组(卵巢切除+阿胶强骨口服液组)血液中25-羟基维他命D3浓度和1,25-羟基维他命D3浓度与B组(卵巢切除+生理盐水组)比较明显增高,其中对25-羟基维他命D3浓度增高尤为明显,已接近A组(假手术组),P=0.002(P＜0.01),差异有明显的统计学意义.荧光定量PCR(FQ-PCR)结果B 组与C组相比,P=0.004(P＜0.01),说明扩增效率的差异有明显的统计学意义.结论 阿胶强骨口服液增加去势大鼠血液中25-OH-VD3、1,25-(OH)2-VD3的浓度,同时上调肝脏中VDR的表达水平,是阿胶强骨口服液治疗骨质疏松的机制之一.“,”Objective To investigate the effects of donkey-hide glue reinforcing bone oral solution (DGRBOS)on serum 25-OH-VD3、1,25-(OH)2-VD3 content and liver VDR gene expression in rats, and accordingly to probe into the efficacy of DGRBOS (donkey-hide glue reinforcing bone oral solution) on osteoporosis. Methods Female Sprague Dawley rats(n=36), aged 6 months, were randomly divided into three groups. Group A were sham operated and given intragastric administration of normal sodium; group B were oophorectomized and given intragastric administration of normal sodium; group C were oophorectomized and given intragastric administration of DGRBOS. Animals were sacrificed after 6 months for determination of the 25-OH-VD3 and 1,25-(OH)2-VD3 concentration in serum by ELISA and quantitative analysis VDR gene expression by Fluorescence quantitative PCR(FQ-PCR). Results We found group C had an obviously elevation of the 25-OH-VD3 and 1,25-(OH)2-VD3 concentration in serum compared with Group B (P=0.002), especially for 25-OH-VD3, which showed similar results from Group A, and VDR gene expression also had a statistical significance between Group B and Group C (P=0.004). Conclusion DGRBOS can increase serum 25-OH-VD3 and 1,25-(OH)2-VD3 concentration in ovariectomized rats, while increase in liver VDR expression, which is a possible mechanism for osteoporosis treatment with DGRBOS.